The short answer is very high risk (CVD "plus"- FH, diabetes, see below) with LDL-C >= 100-130 mg/dl (3.4 mmol/L) and high risk (CVD or FH) with LDL-C >=130 mg/dl.
A has been mentioned in previous posts, PCSK9 monoclonal antibodies are expensive, and payers have been reluctant to approve them, with onerous pre-approval processes.NNTs of 21-25 over 5 years may approach cost-effectiveness thresholds with significant discounting. We described this quantitative approach using NNT for guiding consideration of nonstatin therapy (Robinson JACC 2016). The potential for benefit depends on the absolute CVD risk of the patient and the level of LDL-C (Table).
other patients that are very high risk (>=30% 10-year ASCVD risk) on moderate-high intensity statins include those with clinical CVD "PLUS" (CVD and familial hypercholesterolemia (FH), diabetes, recent acute coronary syndromes, chronic kidney disease, multiple poorly controlled risk factors, polyvascular disease, men >=65 years). The very high risk and high risk groups in our paper generally support those identified in the 2016ACC nonstatin pathway.
Easy one-click social registrationIs this safe?
We only receive the minimum information necessary to verify your account. We never get access to your friends/contacts or your profile, and we never post on your behalf. Your social account is used for logging in only.ORRegister via email
Send me updates on this Contest
In order to ensure a fair voting process and to make sure that no one votes more than once, we ask that you register either with a social networking account (easiest, only requires one click) or by registering with your email address (this will require you to click on a verification email that we will send you).
You only need to register once.